Equity Capital Markets
Equity Capital Markets Group
Industry-Leading Full-Service Equity Capital Markets Group
The Equity Capital Markets Group (ECM) is responsible for originating and executing public and private equity and equity linked offerings as well as SPACs. In 2021, the ECM group managed over 265 equity and equity-linked transactions, including executing 76 IPOs, raising more than $108B. In addition, the ECM team has a leading SPAC business, advising in 2021 on more than 45 transactions within all phases of the Special Purpose Acquisition Company (SPAC) lifecycle, including IPOs, PIPEs, and de-SPAC engagements. The Stifel equity platform brings differentiated institutional access and retail distribution in the US and Internationally.
Stifel is the Leading IPO Bookrunner Among All Middle-Market or Specialist Firms
Learn MoreNotable Transactions
$ 100,000,000
Joint Bookrunning Manager
Registered Direct Offering
Biopharma
Jul 2026
$ 312,195,136
Joint Bookrunning Manager
IPO
Engineering & Construction, and Infrastructure
Jun 2026
$ 283,750,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Jun 2026
$ 805,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Jun 2026
$ 335,800,000
Lead Left Bookrunning Manager
Follow-on Offering
Engineering & Construction, and Infrastructure
Jun 2026
Exclusive Financial Advisor
Has Received a Minority Equity Investment
Automotive Aftermarket
Jun 2026
$ 86,250,000,000
Co-Manager
IPO
Aerospace, Defense & Government Services
Jun 2026
$ 690,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Jun 2026
$ 200,200,000
Joint Lead Bookrunning Manager
IPO
Energy & Natural Resources
Jun 2026
$ 650,000,000
Joint Bookrunning Manager
IPO
Aerospace, Defense & Government Services
Jun 2026
Advisor to Buyer
Mergers & Acquisitions
Engineering & Construction, and Infrastructure
May 2026
$ 117,500,000
Left Bookrunning Manager
Registered Direct
Biopharma
Apr 2026
$ 700,350,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Apr 2026
$ 191,250,000
Joint Bookrunning Manager
Initial Public Offering
Tools & Diagnostics
Apr 2026
$ 254,880,000
Joint Bookrunning Manager
Initial Public Offering
Biopharma
Apr 2026
$ 150,800,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Apr 2026
$ 350,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$ 719,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$ 650,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Mar 2026
$213,037,500
Joint Bookrunning Manager
Follow-on Offering
Energy & Natural Resources
Mar 2026
$ 200,000,000
Joint Bookrunning Manager
Initial Public Offering
Energy & Natural Resources
Feb 2026
$1,150,000,000
Joint Bookrunning Manager
Follow-on and Concurrent Tangible Equity Unit Offering
Aerospace, Defense & Government Services
Feb 2026
$175,000,012
Lead Left Bookrunning Manager
Confidentially Marketed Follow-on Offering
Aerospace, Defense & Government Services
Feb 2026
$ 150,000,000
Joint Bookrunning Manager
Confidentially Marketed Follow-on Offering
Biopharma
Feb 2026
$ 150,000,000
Joint Bookrunning Manager
Follow-on Offering
Biopharma
Feb 2026
Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.